Jingtai Technology has been included in the MSCI China Index and recognized for its development potential as a global investment benchmark

On the morning of November 6th Beijing time, the globally renowned index company MSCI announced the results of its index review for November 2025.Driven by artificial intelligence (AI) and robots, innovation in new drugs and materialsJingtai Technology（2228.HK）Selected to be included in MSCI's most closely watched flagship index - MSCI China Index.This adjustment is based on the review results of its November semi annual index and will officially take effect after the close of trading on November 24, 2025.

The MSCI China Index has added 26 new targets, including multiple onesResource stocks, as well as technology companies such as artificial intelligence, robotics, semiconductors, and high-end manufacturing. Entering the MSCI China Index means entering the MSCI Global Standard Index series, thereby gaining a large amount of passive fund tracking.

The MSCI China Index is one of the key benchmarks for measuring the performance of Chinese large and medium-sized company stocks, widely tracked and referenced by global institutional investors. The selection of its index constituent stocks is based on objective quantitative indicators, including company market value, free circulation, liquidity, and market investability. Being selected for this index indicates that Jingtai Technology meets strict international standards in terms of market capitalization, market representativeness, and liquidity. The company's investment value and growth potential have been recognized by the global capital market authorities.

Jingtai Technology is an innovative research and development platform that deeply integrates quantum physics, artificial intelligence, and large-scale standardized experimental robots, and is also scientifically intelligent（AI for Science）A pioneer in the field, we have established partnerships with over 300 international enterprises, innovative companies, and research institutions, and will achieve profitability in the first half of 2025. Our business scope covers new drugs, energy, agriculture, new materials, new chemicals, consumer goods, and other fields. Jingtai Technology is one of the few AI research and development platforms in the industry that has obtained high-value international pharmaceutical cooperation in both AI small molecule drugs and AI biopharmaceuticals. Among the top 20 global pharmaceutical companies, 17 are customers of Jingtai Technology.

The inclusion in the MSCI China Index this time is a positive recognition of Jingtai Technology's performance in the secondary market, business fundamentals, and future prospects. The company will take this opportunity to continue focusing on building core technological innovation capabilities, consolidating and accelerating the expansion of commercial achievements, creating greater value for global customers and partners, and bringing sustainable long-term returns to investors.